Skip to main content
. 2021 Mar 1;14(3):E53–E57.

TABLE 3.

Summary of TEAEs

FMX103 1.5% (N=20)
Subjects with any TEAE, n (%) 1 (5.0)
Number of TEAEsa 2
Subjects with any treatment-related TEAE, n (%) 1 (5.0)
Number of treatment-related TEAEsb 1
Subjects with any serious TEAE, n (%) 0 (0.0)
Number of serious TEAEs 0
Subjects with any severe TEAE, n (%) 0 (0.0)
Number of severe TEAEs 0
Subjects with any TEAE leading to discontinuation, n (%) 0 (0.0)
Number of TEAEs leading to discontinuation 0

TEAE, treatment-emergent adverse event

aArthralgia (moderate severity), headache (mild severity)

bHeadache